The
Government of India with the assistance of World Bank has
initiated the National Pharmacovigilance Programme. The
Central Drugs Standard Control Organization (CDSCO) is
coordinating the country-wide Pharmacovigilance programme under
the aegis of DGHS, Ministry of Health & Family Welfare, New
Delhi.
With
the number of new drugs being regularly approved for marketing
in India, there is a need for a vibrant Pharmacovigilance system
in the country to protect our population from the potential
harms that may be caused by some of these new drugs. Besides,
with the patent regime coming in force from 2005, it is widely
believed that India would become the global hub for new drug
trials. These situations make it pertinent for the Indian
central drugs regulatory authority to have a vibrant
Pharmacovigilance system in the country.
The
programme shall be coordinated by CDSCO under the supervision of
a National Pharmacovigilance Advisory Committee which would
monitor the program and also recommend regulatory interventions
based on the generated Adverse Drug Reaction (ADR) data.
2. Objective of the
Assignment
Assignment:
To manage the Regional Pharmacovigilance centre (covering *
regions)
The
overall objective as per the National Pharmacovigilance
Programme will be:
1.
To monitor safety of the drugs and provide structured
inputs for appropriateregulatory interventions
2.
To create awareness about ADR monitoring in India
Regional
centres will be the secondary pharmacovigilance centres under
the National Pharmacovigilance Programme.
By
accepting to participate in the National Pharmacovigilance
Programme all centres explicitly agree that all
pharmacovigilance activities at their institutions shall be
performed in strict consonance with the National
Pharmacovigilance Programme appended here (Coordinators of the
centres and heads of the institutions are advised to carefully
go through the Protocol prior to joining the programme).
3. Outline of tasks to
be carried out
The
National Pharmacovigilance Programme encourages the reporting of
all suspected adverse reaction to drugs and other medicinal
substances including herbal, traditional or alternative
remedies. The reporting of seemingly insignificant or common
adverse reactions would be important since it may highlight a
wide spread prescribing problem.
Regional
Centre is expected to carry out the following tasks:
|
S.
No.
|
Task
|
-
|
The
coordinator designated by CDSCO for the Regional Centre for
the program would ensure conformity of his functioning with
the protocols of National Pharmacovigilance program.
|
-
|
Correspond
with Peripheral Centres, provide them with technical support,
coordinate and monitor their functioning.
|
-
|
Collect
& collate Adverse Drug notifications from Peripheral as
well as own centers [those generated at the same centre and
those received from peripheral centres] and forward all
duly-filled ADE forms to Zonal Centre
|
-
|
Ensure
quality of data reported by peripheral centres by carrying
out technical audits to ensure compliance, take corrective
measures and monitor the implementation for corrective
measures.
|
-
|
Organize
and attend training programmes / interactive meetings for all
peripheral centres falling under the respective regional
pharmacovigilance centers
|
-
|
Carryout special projects on
drug safety at the request of the CDSCO.
|
-
|
To provide updates, reports
and such other information as may be required by the National
Pharmacovigilance Advisory Committee and to attend their
meetings when required.
|
-
|
Carry out (and/or review) data
causality analysis of all ADEs
|
-
|
To receive
blank ADE forms form Zonal or National Centre and acknowledge
the receipt
|
-
|
To
maintain log of all ADE forms and ADE notification forms
received and forwarded
|
-
|
To
fill or get filled minimum 50 ADE forms from their own
center.
|
-
|
Inculcate
/ foster the culture of ADE reporting / notification in
health care professionals by acknowledging the cooperation by
the notifier and share with the notifier relevant feedback.
|
-
|
Receive
funds from CDSCO
|
-
|
Maintain
the accounts as per the project requirements and as per your
institution’s systems; to review and consolidate the
account statements of the peripheral centers and complied the
statement of account of their own centre and ensure duly
audited of statement of accounts to zonal center.
|
4. Schedule of
Performance of Tasks
The
duration of the assignment is four year (with a review at the
end of every year). The time schedule for performance of various
tasks is detailed below:
|
S.
No.
|
Task
|
Time
Schedule
|
|
1.
|
The
coordinator designated by CDSCO for the Regional Centre for
the program would ensure conformity of his functioning with
the protocols of National Pharmacovigilance program.
|
One
month from date of appointment
|
|
2.
|
Correspond
with Peripheral Centres, provide them with general technical
support, coordinate and monitor their functioning.
|
One
month from date of appointment
|
|
3.
|
Collect
& collate Adverse Drug notifications from Peripheral as
well as own centers [those generated at the same centre and
those received from peripheral centres] and forward all
duly-filled ADE forms to Zonal Centre
|
Monthly
|
|
4.
|
Monitor
quality of data reported by peripheral centres by carrying
out technical audits to ensure compliance, take corrective
measures and monitor the implementation for corrective
measures.
|
Quarterly
|
|
5.
|
Organize
and attend training programmes / interactive meetings for all
peripheral centres falling under the respective regional
pharmacovigilance centers
|
Six
months in addition to induction training.
|
|
6.
|
Carryout special projects on
drug safety at the request of the CDSCO.
|
Ongoing
|
|
7.
|
To provide updates, reports
and such other information as may be required by the National
Pharmacovigilance Advisory Committee and to attend their
meetings when called
|
Ongoing
|
|
8.
|
Carry out (and/or review) data
causality analysis of all ADEs
|
Monthly
|
|
9.
|
To receive
blank ADE forms form Zonal or National Centre and acknowledge
the receipt
|
Ongoing
|
|
10.
|
To
maintain log of all ADE forms and ADE notification forms
received and forwarded
|
Ongoing
|
|
11.
|
To
fill or get filled minimum 50 ADE forms from their own
center.
|
Monthly
|
|
12.
|
Inculcate
/ foster the culture of ADE reporting / notification in
health care professionals by acknowledging the cooperation by
the notifier and share with the notifier relevant feedback.
|
Ongoing
|
|
13.
|
Receive
funds from CDSCO
|
Ongoing
|
|
14.
|
Maintain
the accounts as per the project requirements and as per your
institution’s systems; to review and consolidate the
account statements of the peripheral centers and complied the
statement of account of their own centre and ensure duly
audited of statement of accounts to zonal center.
|
Quarterly
|
5. Data Services and
Facilities to be provided by CDSCO
CDSCO
shall coordinate the programme and arrange for training for
those professionals who are participating in the programme.
6. Final Output that
will be required
a)
Structured pharmacovigilance data based on the ADE forms
collected under the program participants.
b)
A structured annual report describing smooth and
efficient operation of the program, in accordance with the
Protocol.
7.
Financial support, Manpower and Facilities to be provided
by National Pharmacovigilance Centre at CDSCO H.Q.
The
following financial support and manpower shall be provided by
CDSCO:
1. One post of
Pharmacologist: Minimum qualification: M.Pharm, Desired Qualification: M.Pharm. with
pharmacology or clinical pharmacy.Maximum remuneration of Rs.
15,000.00 (fixed) per month
The
personnel for above post shall be identified and retained by the
Regional centres on contract on year-to-year basis with the
approval of DCG(I).
2. Office Operation
Suport for Zonal center Rs. 25,000.00 p.a.
3. AE Reporting forms,
various books and periodicals, MIS reporting forms shall be
provided by the CDSCO, which will also provide funds for zonal /
regional / peripheral interaction meetings twice a year.
8. Review Committee
The
National Pharmacovigilance Advisory Committee (NPAC) will
oversee the performance of various Zonal, Regional and
Peripheral Centres and will perform the functions of “Review
Committee” for this program.The NPAC will also recommend
possible regulatory measures based on pharmacovigilance data
received from various centres. The composition of the NPAC is as
under:
|
Chairperson
|
Director General Health Services
|
|
Member Secretary
|
DCG(I)
|
|
1.ICMR
|
D. G., ICMR, New Delhi
|
|
2.AIIMS, New Delhi, Zonal Centre Coordinator
|
Dr. S. K. Gupta, Head of the Department of Pharmacology, AIIMS, New
Delhi
|
|
3.SGC Medical College, Mumbai, Zonal Centre Coordinator
|
Dr. Nilima Kshirsagar, SGS Medical College (Mumbai)
|
|
4.Member, Pharmacology
|
Dr. Ranjit Roy Choudhary, NII, New Delhi
Dr. C. Adithan, Prof. Pharmacology JIPMER, Pondicherry
|
|
5. Forensic Medicine
|
Dr. T. D. Dogra, (AIIMS, New Delhi)
|
|
6.General Medicine
|
Dr. A. K. Agarwal (RML, New Delhi)
Dr. Anoop Mishra (AIIMS, New Delhi)
|
|
7.Clinical Pharmacology
|
Dr. S. D. Seth, Chair-in Clinical Pharmacology (ICMR, New Delhi)
|
|
8.Member, Pharmacy
|
Mr. Brijesh Regal, WHO Consultant New Delhi
|
|
9.Member, Toxicology
|
Dr. Y. K. Gupta, Director, (ITRC, Lucknow)
|
|
10. Member, Epidemiology
|
Dr. M. D. Gupte (ICMR Institute of Epidemiology, Chennai)
|
|
11. Member, Pathology
|
Dr. Kusum Verma Member Secretary, (AIIMS Ethics Committee, New Delhi)
|
|
12. Member, Drug Information
|
Dr. Pramil Tiwari (NIPER, Mohali)
|
|
13. Member, Phytotherapy
|
Dr. Urmila Thatte, Head of the Department of Pharmacology, B. L. Nair
Medical College Hospital, Mumbai
|
9. MIS Formats for
Reporting by Regional Centre to Zonal Centre
1.
Period of Report
2.
Number of notifications received in the preceding period
3.
Number of Reports made and number of serious or suspected
serious AEs reports, if any
4.
Number of serious or suspected serious AE reports
forwarded with in the specified time
5.
Number of serious or suspected serious AE reports not
forwarded with in the specified time along with the reasons for
delay
6.
Important happenings or development (events that happened
other than the way they should have happened or the events that
did not happen other than the way they should have happened)
7.
Total number of AEs forms received
8.
Number of recommendations from Peripheral
Pharmacovigilance centres for new peripheral pharmacovigilance
centre
9.
Total no. of AE forms received from Peripheral Centre in
which causality assessments has been made
10.
Number of AE forms received from Peripheral Centre in
which causality assessment has been verified / reassessed
11.
Number of forms archived
12.
Monitoring activities done
13.
No. of notifications / reports received from each centre
14.
No. of reports filled in inappropriately by respective
Peripheral Centres
15.
Actions taken / recommended
16.
Acknowledgements sent in time
17.
CME awareness activities if any
18.
Any other observations